CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Fecal Microbiota Therapy in Canada: Barriers and Facilitators to Access

Last updated: September 17, 2020
Project Number: ES0341-000
Product Line: Environmental Scans
Research Type: Device
Result type: Report
Expected Completion Date: September 17, 2020

Evidence supports the use of fecal microbiota transplant (FMT) for recurrent Clostridium difficile (C. difficile) infection. Information on the potential of FMT for treating other conditions, such as inflammatory bowel disease, ulcerative colitis, and Crohn disease, is also emerging. Given this, the indications and demand for FMT may increase in the future; however, the infrastructure and standardized processes needed to provide this therapy are not yet in place across Canada. This Environmental Scan identifies the current state of access to FMT in Canada, and the barriers and facilitators to providing this treatment.